Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)

E. Hamilton; J. Meisel; C. Alemany; B. Virginia; N. Lin; R. Wesolowski; G. Mathauda-Sahota; D. Makower; J. Lawrence; D. Faltaos; Z. Mitri; D. Sabanathan; D. Clark; T. Pluard; R. Hui; N. McCarthy; M. Patel

doi:10.1016/S0959-8049(22)00896-6

Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)

E. Hamilton, J. Meisel, C. Alemany, B. Virginia, N. Lin, R. Wesolowski, G. Mathauda-Sahota, D. Makower, J. Lawrence, D. Faltaos, Z. Mitri, D. Sabanathan, D. Clark, T. Pluard, R. Hui, N. McCarthy, M. Patel

Oncology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	S36
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)00896-6
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0959-8049(22)00896-6

Cite this

Hamilton, E., Meisel, J., Alemany, C., Virginia, B., Lin, N., Wesolowski, R., Mathauda-Sahota, G., Makower, D., Lawrence, J., Faltaos, D., Mitri, Z., Sabanathan, D., Clark, D., Pluard, T., Hui, R., McCarthy, N., & Patel, M. (2022). Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). European Journal of Cancer, 174, S36. https://doi.org/10.1016/S0959-8049(22)00896-6

Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). / Hamilton, E.; Meisel, J.; Alemany, C. et al.
In: European Journal of Cancer, Vol. 174, 10.2022, p. S36.

Research output: Contribution to journal › Article › peer-review

Hamilton, E, Meisel, J, Alemany, C, Virginia, B, Lin, N, Wesolowski, R, Mathauda-Sahota, G, Makower, D, Lawrence, J, Faltaos, D, Mitri, Z, Sabanathan, D, Clark, D, Pluard, T, Hui, R, McCarthy, N & Patel, M 2022, 'Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)', European Journal of Cancer, vol. 174, pp. S36. https://doi.org/10.1016/S0959-8049(22)00896-6

Hamilton E, Meisel J, Alemany C, Virginia B, Lin N, Wesolowski R et al. Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). European Journal of Cancer. 2022 Oct;174:S36. doi: 10.1016/S0959-8049(22)00896-6

@article{766ff0e445d043a5be84af201996c55e,

title = "Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)",

author = "E. Hamilton and J. Meisel and C. Alemany and B. Virginia and N. Lin and R. Wesolowski and G. Mathauda-Sahota and D. Makower and J. Lawrence and D. Faltaos and Z. Mitri and D. Sabanathan and D. Clark and T. Pluard and R. Hui and N. McCarthy and M. Patel",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)00896-6",

language = "English (US)",

volume = "174",

pages = "S36",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)

AU - Hamilton, E.

AU - Meisel, J.

AU - Alemany, C.

AU - Virginia, B.

AU - Lin, N.

AU - Wesolowski, R.

AU - Mathauda-Sahota, G.

AU - Makower, D.

AU - Lawrence, J.

AU - Faltaos, D.

AU - Mitri, Z.

AU - Sabanathan, D.

AU - Clark, D.

AU - Pluard, T.

AU - Hui, R.

AU - McCarthy, N.

AU - Patel, M.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140470232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140470232&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00896-6

DO - 10.1016/S0959-8049(22)00896-6

M3 - Article

AN - SCOPUS:85140470232

SN - 0959-8049

VL - 174

SP - S36

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this